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Abstract
Purpose Pathological parameters assessed on biopsies and resection specimens have a pivotal role in the diagnosis, prognosis 
and management of patients with renal cell carcinoma (RCC).
Methods A non-systematic literature search was performed, updated to January 2018, to identify key standards and contro-
versies in the pathological classification, grading and staging of RCC.
Results Although most RCCs exhibit characteristic morphology that enables easy categorisation, RCCs show considerable 
morphological heterogeneity and it is not uncommon for there to be difficulty in assigning a tumour type, especially with 
rarer tumour subtypes. The differentiation between benign and malignant oncocytic tumours remains a particular challenge. 
The development of additional immunohistochemical and molecular tests is needed to facilitate tumour typing, because of 
the prognostic and therapeutic implications, and to enable more reliable identification of poorly differentiated metastatic 
tumours as being of renal origin. Any new tests need to be applicable to small biopsy samples, to overcome the heterogene-
ity of renal tumours. There is also a need to facilitate identification of tumour types that have genetic implications, to allow 
referral and management at specialist centres. Digital pathology has a potential role in such referral practice.
Conclusion Much has been done to standardise pathological assessment of renal cell carcinomas in recent years, but there 
still remain areas of difficulty in classification and grading of these heterogeneous tumours.
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Introduction
Pathological parameters assessed on biopsies and resec-
tion specimens have a pivotal role in the diagnosis, prog-
nosis and management of patients with renal cell carcinoma 
(RCC). Standardisation of specimen handling and patho-
logical assessment is, therefore, critical to ensuring that 
the information contained within histopathology reports is 
accurate and consistent, for both diagnostic and research 
purposes. Although various local and national guidelines 
have been utilised in clinical practice for many years, several 
recent initiatives have done much to improve consistency 
at an international level, enabling pathologists to provide 
the high-quality information required. In 2016, the WHO 
published a fourth edition of its classification of urological 
tumours, which is the current internationally recommended 
system for typing of renal tumours [1]. The updated version 
of this ‘Blue book’ also provides epidemiological, clinical 
and pathological information on the wide range of renal 
tumours that may be encountered in clinical practice.
Methods
A non-systematic literature search was conducted using 
Medline. The reference lists of selected manuscripts were 
checked manually for eligible articles. The most contempo-
rary guidelines and relevant articles are included, updated 
to January 2018.
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In 2012, the European Network of Uropathology (ENUP) 
published a survey of the practice of handling nephrectomy 
specimens by pathologists from 15 European countries [2]. 
This was followed in the same year by an International Soci-
ety of Urological Pathology (ISUP) consensus conference 
on renal tumour pathology in Vancouver. Members of the 
Society were asked to complete a pre-meeting questionnaire 
on all aspects of their practice of specimen handling and 
pathological reporting of renal tumours. The results were 
presented at the conference by a panel of experts and were 
discussed and voted upon to determine what should be con-
sidered best practice. Following this conference, a series of 
ISUP publications has provided valuable guidance on speci-
men handling, tumour typing, grading and assessment of 
prognostic factors [3–8]. Subsequently, ISUP guidance for 
pathologists on best practice for use of routine immunohis-
tochemistry in the assessment of renal cell tumours has also 
been published [9, 10].
In addition, the International Committee for Cancer 
Reporting (ICCR) has devised a series of international data-
sets for pathologists reporting tumour pathology, with the 
renal tumour datasets published in 2017 [11, 12]. In the UK, 
the third edition of the Royal College of Pathologists dataset 
for renal cancer reporting was published in 2017 [13]. Simi-
lar protocols are readily available from, for example, the Col-
lege of American Pathologists (www.cap.org) and the Royal 
College of Pathologists of Australasia (www.rcpa.edu.au). 
These datasets contain guidance on which evidence-based 
‘core’ pathological data items should always be included 
in histopathology reports, to provide the essential informa-
tion required for patient management. Other items are also 
recommended for reporting, but are considered ‘non-core’ 
optional data at present due to insufficient evidence of their 
prognostic significance.
Pathological parameters and stage
The main core items included in renal tumour pathology 
reports, currently deemed essential for patient management, 
are discussed below.
Tumour type
The 2016 WHO classification of renal tumours is based on 
a combination of morphological, molecular and genetic fea-
tures [1]. RCCs represent the most common renal tumour in 
adults and are divided into a number of different histological 
types. The most common is the clear cell type (70–90%), 
followed by papillary (10–15%) and chromophobe RCCs 
(3–5%). Many studies, including large multicentre studies, 
have shown that tumour type has prognostic significance [6, 
14–20]. Tumour type also has utility in selection of patients 
for adjuvant therapy, further underlining the importance 
of assigning tumours to the correct category on pathologi-
cal assessment [21]. The major tumour types are discussed 
below, with their key pathological features, as well as rarer 
tumours that have differing clinical significance and may 
cause diagnostic difficulty.
Clear cell RCC has a worse prognosis than papillary or chro-
mophobe RCCs, when matched for stage, and is more likely 
to present at an advanced stage or with existing metastases 
[20, 22–24]. In 90% of cases, these tumours exhibit altera-
tions in the von Hippel–Lindau tumour suppressor (VHL) 
gene on chromosome 3 [25]. Most tumours are sporadic, but 
multiple bilateral tumours are seen in von Hippel–Lindau 
syndrome, a rare autosomal dominant condition also associ-
ated with a variety of other tumours that include haeman-
gioblastomas of the retina and central nervous system [26]. 
Multifocal sporadic tumours are rare and a recent study has 
shown that apparent multifocality may be due to retrograde 
venous invasion from a single tumour [27]. Grossly, clear 
cell RCCs characteristically contain solid yellow areas with 
variable amounts of cystic change, haemorrhage and necro-
sis. Although on microscopy they are classically composed 
of clear cells set within a fine intricate vascular network, 
they may consist entirely of cells with eosinophilic granular 
cytoplasm, particularly if high grade. On immunohistochem-
istry they characteristically co-express pan-cytokeratin and 
vimentin and are carbonic anhydrase IX (CA-IX) positive, 
but are usually Cytokeratin 7 (CK7) negative. The multi-
locular cystic renal neoplasm of low malignant potential was 
formerly included in the clear cell carcinoma category, but 
is now known to have indolent behaviour and an excellent 
prognosis, regardless of size, with no reported metastases 
[6, 28]. It is rare (< 1% of renal tumours), but is readily 
diagnosed if morphological criteria are strictly adhered to 
[1]. These cystic tumours characteristically have thin fibrous 
septae containing low-grade clear cells, but no solid expan-
sile clear cell nodules that are seen in clear cell RCC. They 
have been shown to have chromosome 3p deletions and VHL 
gene mutations similar to clear cell RCCs [1]. Correct patho-
logical diagnosis of these tumours is important, as they may 
be managed conservatively.
Papillary RCCs are grossly solid, with or without cystic 
change or encapsulation, and are often grey or brown in col-
our with a soft friable cut surface showing frequent necrosis 
and haemorrhage. On microscopy, according to the current 
WHO classification, they are divided into type 1 or type 2 
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tumours, determined primarily by their differing cytological 
features, and mixed patterns occur [1, 6, 29]. An oncocytic 
variant (composed of cells with abundant eosinophilic/pink 
cytoplasm) has also been described morphologically, but is 
included under the general category of papillary RCC in this 
classification system [1, 18].
Type 1 papillary RCCs usually consist of papillary struc-
tures lined by cuboidal cells with low-grade nuclei. Collec-
tions of foamy macrophages are often present within the 
papillary fibrovascular cores and calcifications (psammoma 
bodies) and intracellular haemosiderin are common. They 
may also show solid growth, with very compact papillary 
structures. The tumours have a typical profile on immuno-
histochemistry, including strong CK7 and alpha-methyla-
cyl-CoA racemase (AMACR) expression and at most focal 
CA-IX expression. At the molecular level, type 1 tumours 
typically show gains in chromosomes 7 and 17, and Y chro-
mosome loss. Most tumours are sporadic, but there are 
familial cases in the autosomal dominant hereditary papil-
lary RCC syndrome, where germline MET proto-oncogene 
mutations on chromosome 7 result in multiple bilateral 
tumours [30]. Extrarenal manifestations are not a feature 
of this familial syndrome [30]. Type 1 tumours generally 
present with a lower grade and stage at diagnosis and have a 
better outcome than type 2 tumours [31]. Tumours with the 
histological appearance of a non-encapsulated type 1 tumour 
and up to 15 mm in size are classified as papillary adenomas, 
rather than carcinomas, because they show benign clinical 
behaviour [1].
Morphologically, type 2 tumours have cells with more 
abundant eosinophilic cytoplasm that show nuclear pseu-
dostratification and higher grade nuclei. They also show 
more variable protein expression on immunohistochem-
istry than type 1 tumours, often including loss of CK7. 
At the molecular level, these tumours are associated with 
NRF2–ARE pathway activation and can be divided into 
several distinct molecular subtypes that are associated with 
differing patient survival. Papillary RCCs are now known to 
represent a much more heterogeneous group of tumours than 
implied by the 2016 WHO classification [32, 33]. A recent 
study by Saleeb et al. suggests that using a combination 
of morphological features, immunoprofiles and molecular 
analysis, papillary RCCs can be divided into four subtypes 
and that this type of grouping would be a better means of 
guiding patient management [34].
Papillary RCC is more often multifocal and bilateral than 
the other common tumour types, as seen in approximately 
10% of cases [6]. Papillary RCCs are also more frequent in 
acquired cystic kidney disease.
A less common tumour that may show overlapping mor-
phology with type 1 papillary RCCs, particularly in limited 
biopsy samples, is the mucinous tubular and spindle cell 
carcinoma (MTSCC) [1]. This is classically composed of 
elongated tubules and spindle cells, both cytologically low 
grade, and abundant intercellular mucin. It has a similar 
immunohistochemical profile to papillary RCCs, adding to 
the difficulty in distinguishing these tumours in some cases. 
Ren et al. have, however, demonstrated that MTSCCs show 
multiple chromosome losses and lack trisomy 7 and 17, ena-
bling separation on molecular studies [35]. These tumours 
are more common in females and generally exhibit indolent 
behaviour, but distant metastases have been reported [1, 18].
Chromophobe RCC is usually sporadic and generally has a 
good prognosis. Most of these tumours are confined to the 
kidney at diagnosis, though they may be large at the time 
of presentation [36]. They are characteristically tan in col-
our, similar to the benign renal oncocytoma that is the main 
differential diagnosis. On microscopy, chromophobe RCCs 
characteristically consist of large cells with prominent cell 
membranes, pale cytoplasm and crinkled ‘raisinoid’ nuclei 
with perinuclear halos. An eosinophilic variant also occurs, 
where the cells have an oncocytic cytoplasmic appearance 
and the nuclear features described are often less apparent. 
Chromophobe RCCs are characterised by multiple chromo-
some copy number alterations [37]. Hybrid oncocytic-chro-
mophobe tumours, with a mixed morphology, may occur 
sporadically or in the Birt–Hogg–Dubé syndrome. The lat-
ter shows autosomal dominant inheritance and is associated 
with FLCN gene mutations on chromosome 17 [6, 18, 26]. 
There are associated cutaneous lesions, pulmonary cysts 
and spontaneous pneumothoraces [30]. The hybrid renal 
tumours are usually small and show indolent behaviour and 
are amenable to conservative management [38]. A variety 
of other renal tumour types have also been reported in this 
syndrome [30].
Collecting duct carcinoma is a rare (1–2%) and highly 
aggressive type of RCC arising in the renal medulla. It may 
be difficult to distinguish histologically from urothelial car-
cinoma of the renal pelvicalyceal system, due to similar 
infiltrative high-grade variable morphology and their over-
lapping immunohistochemistry profiles. Distinction from 
metastatic tumours may also be problematic, particularly 
adenocarcinomas, and diagnosis is by exclusion of other 
entities. Metastatic disease is common at the time of diagno-
sis and the majority of patients do not survive 2 years from 
diagnosis [1, 18]. Renal medullary carcinoma has similar 
morphology and occurs in association with sickle cell trait 
or disease. This is rare, aggressive and occurs more often in 
younger adults. In contrast to collecting duct carcinomas, 
these tumours may express OCT3/4 on immunohistochemis-
try and show loss of expression of SMARCB1 (INI1) [1, 39].
MiT family translocation RCCs are rare and should be con-
sidered particularly in children and young adults presenting 
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with RCC, although they also occur in the adult population 
[40]. They result from gene fusions involving the MiT tran-
scription factor genes TFE3 and TFEB, with differing fusion 
partners. The best morphologically described tumours of the 
group are those associated with Xp11 and t(6;11) translo-
cations. The former may be recognised by their distinctive 
clear cell morphology with voluminous cells, and a pap-
illary architecture, sometimes with frequent calcifications 
(psammoma bodies). The less common t(6;11) translocation 
tumours have a characteristic biphasic pattern with distinct 
groups of large and small epithelioid cells. The MiT family 
translocation RCCs commonly show weak expression of epi-
thelial markers on immunohistochemistry and some express 
melanoma markers and cathepsin-K. Diagnosis requires 
fluorescence in situ hybridisation (FISH) to confirm the 
presence of the translocation, as use of immunohistochem-
istry has proven technically challenging. They may exhibit 
aggressive clinical behaviour, particularly in adults or those 
with the Xp11 translocation, and tend to develop early nodal 
metastases [1, 18, 36, 41]. They may be erroneously clas-
sified pathologically as clear cell RCCs, particularly when 
occurring in the adult population. This is of clinical signifi-
cance, as they may not respond to the vascular endothelial 
growth factor (VEGF)-targeted treatments.
Newly recognised types A number of provisional tumour 
types recognised at the 2012 ISUP Vancouver consensus 
meeting have been included as separate entities in the 2016 
WHO classification, as their morphology, immunoprofile 
and molecular characteristics are now better understood [1, 
6]. These include the clear cell papillary RCC that shows 
indolent behaviour, with no reported local recurrences or 
metastases, but would have been previously diagnosed as a 
clear cell RCC [42]. These are usually small tumours and 
are often cystic with compact tubulo-papillary solid areas. 
A distinctive morphological feature is the linear orientation 
of tumour cell nuclei away from the basement membranes, 
although a similar appearance may be seen focally in clear 
cell RCCs. On immunohistochemistry they are strongly CK7 
positive, unlike most clear cell RCCs, high molecular weight 
cytokeratin positive, AMACR negative and exhibit a dis-
tinct ‘cup-shaped’ staining pattern with CA-IX. Molecular 
studies show them to be distinct from clear cell and papil-
lary RCCs [1]. They occur sporadically or in association 
with acquired cystic renal disease and are now recognised 
as being the fourth most common type of renal cell car-
cinoma [42]. Another tumour occurring more frequently 
in the clinical setting of acquired cystic kidney disease is 
the acquired cystic kidney disease-associated RCC. These 
tumours usually show indolent behaviour unless exhibiting 
high-grade features. They often appear to arise within a cyst 
and are commonly multifocal and bilateral. Characteristic 
morphological features are a ‘sieve-like’ architecture and 
the presence of abundant oxalate crystals [1]. They are typi-
cally AMACR positive, but CK7 and CA-IX negative. They 
frequently occur with other renal tumour types [43].
Tubulocystic RCC is another rare, usually indolent, good 
prognosis tumour type more frequently seen in men. It was 
thought to be related to papillary RCCs, but is now accepted 
as a separate entity [1, 44]. It has a characteristic ‘bubble 
wrap’ appearance grossly, due to the presence of fibrotic 
stroma separating cystic spaces. Small tubules are present 
within the stroma microscopically and are lined by cells with 
eosinophilic cytoplasm and round nuclei with nucleoli of 
variable prominence. The tumour cells may also have a ‘hob-
nail’ appearance [1, 18]. These tumours express AMACR 
and CK7 on immunohistochemistry. On molecular analy-
sis, there have been conflicting reports, but in recent series 
of RCCs with a pure tubulocystic morphology, trisomy of 
chromosomes 7 and 17 observed in papillary RCCs was not 
present and these tumours have also been shown to have a 
molecular signature distinct from the more common RCC 
tumour types [45–47]. Other tumours may show areas with 
a tubulocystic pattern, including papillary RCCs, hereditary 
leiomyomatosis renal cell carcinoma-associated RCC, the 
MiT family translocation RCCs, collecting duct carcinoma 
and unclassified RCCs, causing diagnostic difficulty, but 
such tumours with mixed morphology are not included in 
this tumour category.
Hereditary tumours Less than 5% of renal cell carcinomas 
are associated with hereditary syndromes [30, 48]. In addi-
tion to those occurring in the previously described von Hip-
pel–Lindau, hereditary papillary renal cell carcinoma and 
Birt–Hogg–Dubé syndromes, there are also a number of 
more recently recognised hereditary renal tumours.
Succinate dehydrogenase-deficient RCC is rare and results 
from inherited germline mutations in the succinate dehy-
drogenase (SDH) gene, most commonly SDHB but also 
in SDHA, SDHC and SDHD. Affected patients may also 
present with paragangliomas and gastrointestinal stromal 
tumours (GISTs). The associated RCCs may be multifo-
cal and bilaterality occurs in around 25% of cases [49]. On 
microscopy, the RCCs are usually solid and are composed 
of cells with eosinophilic cytoplasm with distinctive cyto-
plasmic vacuolation and inclusions, although focal limited 
presence of these changes may hamper pathological recogni-
tion [50]. Intratumoral mast cells are also a common feature. 
Immunohistochemistry for demonstration SDHB is avail-
able, where a loss of staining is indicative of a mutation in 
the SDHB (most common), SDHC or SDHD genes. SDHA 
gene mutation can be demonstrated by additional absence 
of staining for SDHA. Most tumours are low grade and have 
a good prognosis, but those exhibiting high-grade features, 
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sarcomatoid morphology or necrosis may show aggressive 
behaviour, with a high rate of metastasis up to 70% [1, 50].
Patients with RCC associated with hereditary leiomy-
omatosis and renal cancer syndrome have an autosomal 
dominant inherited germline mutation in the FH gene on 
chromosome 1 that encodes for fumarate hydratase [26, 30]. 
This syndrome is also associated with cutaneous and uterine 
leiomyomata, occurring at greater frequency than the associ-
ated RCCs. These tumours are high grade and often have a 
papillary architecture, with tumour cells having eosinophilic 
cytoplasm. However, the morphology may be very variable 
and lead to misdiagnosis, for example, as an unclassified 
RCC, collecting duct carcinoma or type 2 papillary RCC, 
particularly as they may be solitary and, therefore, not sus-
pected to be part of a hereditary syndrome [51]. A char-
acteristic histological feature is the presence of distinctive 
prominent nucleoli with perinucleolar halos, exhibiting an 
appearance reminiscent of cytomegalovirus inclusions [52]. 
On immunohistochemistry, the combination of a lack of FH 
expression and overexpression of S-(2-succino)cysteine 
(2SC) suggests a diagnosis of FH-deficient RCC, which can 
then be confirmed with molecular studies. These are highly 
aggressive tumours, even when of small size, and show 
frequent distant metastases [30, 53]. Cases of FH-deficient 
RCC that are not obviously associated with the hereditary 
syndrome have been shown to have a similar presentation 
and clinical course. It has, therefore, been suggested that 
germline testing and counselling should also be undertaken 
in these cases when diagnosed pathologically [54, 55].
The tuberous sclerosis complex is associated with muta-
tions in the TSC1 (on chromosome 9) or TSC2 (on chromo-
some 16) genes encoding for hamartin or tuberin, respec-
tively, and shows autosomal dominant inheritance with 
variable penetrance. A variety of associated tumour types 
typically involve the skin, brain, retina, heart or kidney. The 
most common tumours in the kidneys are multiple angiomy-
olipomas, but RCC also occurs rarely and at a younger age 
than sporadic tumours [56, 57]. The RCCs in this syndrome 
have been described as exhibiting three differing morpho-
logical growth patterns: the most common are RCCs with 
prominent smooth muscle stroma and voluminous clear cells 
with a tubulopapillary growth pattern, and the others resem-
ble chromophobe-like RCCs or are similar to the sporadic 
eosinophilic solid and cystic RCC which is further described 
below [56]. The tumours show indolent behaviour. Previ-
ously undiagnosed tuberous sclerosis complex may be sus-
pected if such tumours are seen in combination with multiple 
angiomyolipomas.
Other tumour types There are several other tumour types 
that have been described in recent years, but are not cur-
rently recognised as separate entities in the WHO classi-
fication. The eosinophilic solid and cystic RCC is a rare 
tumour predominantly occurring in adult females, with a 
broad age range [58, 59]. Paediatric cases have also been 
described [60]. It occurs sporadically and is identical to a 
group of tumours occurring in patients with the tuberous 
sclerosis complex. Morphologically it is characterised by a 
solid and cystic growth pattern, with constituent cells having 
voluminous eosinophilic cytoplasm with prominent granular 
stippling. The tumour is distinct in frequently showing CK20 
positivity and typically a lack of expression of CA-IX and 
CK7. Limited molecular studies have demonstrated recur-
ring copy number alterations and TSC1 or TSC2 mutations 
in the sporadic tumours [59, 61, 62]. The tumours usually 
show indolent behaviour, but metastatic disease has been 
reported [60].
A number of other tumours of which there is limited 
experience at present include thyroid-like follicular RCCs, 
RCCs with angioleiomyomatous stroma, the oncocytic RCC 
that occurs post-neuroblastoma treatment and RCCs exhib-
iting ALK gene rearrangements, monosomy 8 and TCEB1 
mutations [1].
Unclassified RCC Approximately 5% of tumours remain 
difficult to categorise after thorough sampling and immu-
nohistochemical assessment, because the tumour is purely 
sarcomatoid, the immunoprofile is not definitive or there 
are unusual or overlapping morphological features. Tumours 
composed of eosinophilic cells have been shown to cause 
particular difficulty in classification when they do not show 
distinctive features [63]. Such tumours are placed in the 
‘unclassified’ category. This category will include both 
low- and high-grade tumours; therefore, pathologists are 
advised to describe the findings, so that it is clear in pathol-
ogy reports at which end of the grading spectrum the unclas-
sified tumour lies.
Challenges in tumour typing
Although most RCCs exhibit characteristic morphology that 
enables easy categorisation, with or without the assistance 
of routine immunohistochemistry, it is not uncommon for 
there to be difficulty in assigning a tumour type. RCCs show 
considerable morphological heterogeneity, with clear cells, 
oncocytic cells or a papillary architecture seen in a variety 
of renal tumours. A particularly problematic area is the sepa-
ration of oncocytic tumours, where benign and malignant 
entities may have overlapping morphology. It is well known 
that distinguishing a benign renal oncocytoma from a chro-
mophobe RCC may be difficult, particularly as fat invasion 
or vascular involvement, features normally associated with 
malignancy, does not necessarily exclude the diagnosis of 
an oncocytoma [64]. CK7 immunohistochemistry may help, 
as oncocytomas should show only focal staining whereas 
there is strong and diffuse staining in most chromophobe 
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RCCs. Fluorescence in situ hybridisation (FISH) can also 
be utilised, as multiple chromosome abnormalities typically 
occur in chromophobe RCCs, but this investigation is not 
necessarily routinely available. Even expert renal tumour 
pathologists report problems in this area, with only 64% of 
a group of world experts willing to definitively report benign 
oncocytomas on biopsy samples [65].
Panels of antibodies are used in immunohistochemistry 
to aid classification of tumours lacking typical morphology. 
However, routinely available antibodies do not exclusively 
stain one particular tumour type, thus creating diagnostic 
difficulty when the immunoprofile is not conclusive. In 
addition, some antibody stains may be positive adjacent to 
areas of necrosis, such as CA-IX or CK7, thus there may be 
aberrant staining in partly necrotic tumours in which these 
antibodies are usually negative, leading to misinterpretation 
of results.
Furthermore, high-grade tumours, particularly in a meta-
static setting, may lose characteristic morphological features 
and immunoprofiles, making confirmation of renal origin 
and tumour subtyping difficult. Pax-8 is helpful for deter-
mining renal origin, but is also positive in tumours from 
other sites, such as the thyroid gland and gynaecological 
tract tumours of Müllerian origin. Additionally, the rarity of 
some tumours, which may show only subtle morphological 
changes from the more common RCC types, makes it dif-
ficult to ensure that pathologists are able to recognise these 
unusual tumour types. In current practice, those tumours 
that do not exhibit sufficiently characteristic morphological 
features or immunoprofiles to allow confident categorisa-
tion into one of the known tumour types, therefore, remain 
‘unclassified’.
Tumour grade
The Fuhrman grading system, assessing nuclear and nucleo-
lar features, has been in international use for many years 
[66]. Although it has proven prognostic utility, intra- and 
inter-observer reproducibility has been problematic, due 
to difficulties in consistently applying the four grades as 
described morphologically [67–70]. A new WHO/ISUP 
grading system has been introduced following the conclu-
sions of the 2012 ISUP Vancouver conference and is recom-
mended for use by the WHO [1, 5]. This is also a four-grade 
system, with the degree of nucleolar prominence assessed 
to determine grades 1–3 and the presence of highly atypical 
‘pleomorphic’ cells and/or sarcomatoid or rhabdoid mor-
phology (see below) defining grade 4. The tumour grade is 
assigned according to the highest grade cells present, rather 
than the most predominant. In practice, the new WHO/ISUP 
grading, though similar to the Fuhrman system, is easier 
to apply and should be more reproducible and clinically 
relevant.
The WHO/ISUP grading system only applies to clear cell 
and papillary RCCs, as its prognostic utility has not been 
validated for other tumour types [67–70]. Although differ-
ent grading systems have been proposed for chromophobe 
RCC, to date, none have been internationally accepted for 
use in clinical practice [71, 72]. Collecting duct carcinomas 
are not graded, as by definition they are aggressive high-
grade tumours. Grading of RCCs should be more consistent 
following the introduction of the WHO/ISUP grading sys-
tem. However, grading is still subject to variation depending 
upon the extent of sampling of tumours, which may show 
only focal high-grade areas, and an individual pathologist’s 
microscopic assessment.
It has been proposed, though not formally accepted, that 
tumour necrosis should be incorporated into the WHO/ISUP 
grading system, to further refine the prognostic significance 
of tumour grades, as some studies have shown that the pres-
ence or absence of necrosis influences prognosis within a 
specific tumour grade [73, 74]. More recently, the prognostic 
relevance of the different morphological patterns observed in 
clear cell RCC has lead to the proposal of a different grading 
system based on tumour architecture [75].
Tumour necrosis
Tumour necrosis is included in prognostic algorithms for 
patient management, but only histological coagulative 
necrosis is recognised to have prognostic significance, as 
grossly visible tumour necrosis is possibly due to a differ-
ent mechanism (probable infarction due to the presence of 
tumour thrombus) [76]. Tumour necrosis has been shown 
to have prognostic significance for clear cell and chromo-
phobe RCCs, independent of tumour stage and grade [5, 22, 
77–79]. Papillary RCCs often contain areas of necrosis and 
its presence in this tumour type, therefore, lacks the same 
significance. However, a study of a series of type 1 papil-
lary RCCs by Peckova et al. demonstrated a good clinical 
outcome for cystic and extensively necrotic tumours [80]. 
Necrosis has also been shown to be an adverse prognos-
tic factor in t(6,11) translocation RCCs [81]. A study by 
Collins and Epstein of RCCs with extensive necrosis has, 
however, shown the situation to be more complex, with 
widespread cystic necrosis in high-grade tumours associated 
with a worse prognosis, but suggesting a good prognosis for 
low-grade tumours where the tumour type, grade and stage 
have greater prognostic significance [82]. Necrosis may also 
influence treatment efficacy, as, for example, the response 
to VEGF/tyrosine kinase inhibitor-targeted therapy has been 
shown to be poor in patients with metastatic disease where 
there was 10% or more necrosis in the primary clear cell 
RCC [83].
The quantity of tumour necrosis has been reported to 
affect the prognostic significance, not simply its presence 
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[84–86]. However, although it has been recommended that 
the proportion of necrosis is recorded in histology reports, 
there is no international agreement as yet on how this can 
be reliably assessed pathologically [5].
Sarcomatoid and rhabdoid morphology
High-grade morphological features, such as the presence of 
cells with a sarcomatoid appearance, are associated with a 
poor outcome, with 15–22% 5-year survival reported and 
distant metastases commonly present at diagnosis (45–77%) 
[5, 87–90]. On histology, the most common pattern seen is 
a spindle cell sarcoma morphology; however, any pattern of 
sarcoma may be seen, including fibrosarcoma, chondrosar-
coma and many others [91]. This appearance may be pre-
sent in any of the main tumour types, occurring in approxi-
mately 5% of cases [5]. There is no minimum amount of 
sarcoma that needs to be seen to record this component. 
Tumours consisting only of sarcomatoid cells are placed in 
the ‘unclassified’ category in the WHO classification [1]. 
The extent of sarcomatoid morphology has been shown to 
adversely affect survival, but there is no international agree-
ment on how this can be measured and reported reliably 
[92, 93].
Rhabdoid morphology refers to the presence of large 
atypical cells with eccentric nuclei. Its presence is also 
reported to be associated with a poor prognosis [94–96]. 
It may occur in any RCC type, but is most commonly seen 
in clear cell RCCs [97]. At the molecular level, an asso-
ciation has been shown between the rhabdoid phenotype 
and alterations in the switch/sucrose nonfermentable (SWI/
SNF) chromatin modelling complex, similar to that noted in 
aggressive carcinomas from other sites exhibiting a rhabdoid 
or undifferentiated phenotype [98].
Sarcomatoid and rhabdoid cells may occur together and 
are both classified as WHO/ISUP grade 4 [1]. The presence 
of sarcomatoid morphology has, however, been shown to 
have a more significant association with death from RCC 
than the presence of rhabdoid morphology [99].
Tumour stage
Pathological tumour stage (TNM) is the most important 
prognostic factor for RCC and is derived from assessment 
of macroscopic and microscopic features [14, 100]. These 
include the tumour size and determination of the presence 
or absence of invasion into the perinephric fat, the renal 
sinus or Gerota’s fascia, involvement of the renal vein or 
inferior vena cava, direct invasion of or metastatic spread to 
the adrenal gland and lymph node metastases.
The 7th editions (TNM7) of the Union for International 
Cancer Control (UICC) and the American Joint Committee 
on Cancer (AJCC) TNM staging systems have been in use 
worldwide for over 7 years and have been validated in clini-
cal practice [101, 102].
Recently, the 8th editions (TNM8) of the alternative 
UICC and AJCC staging systems were published [103, 104]. 
Initially, there were a number of differences between the two 
in a range of tumour sites, including urological tumours, but 
following publication of errata, the pathological TNM stage 
is now closely aligned for renal tumours, although signifi-
cant differences still exist in the prognostic stage groupings 
[105, 106]. TNM8 has been recommended for use from 1st 
January 2018 [103, 104]. Although much of the TNM patho-
logical staging remains unchanged in TNM8, there are a few 
significant changes from TNM7 which are mentioned in the 
relevant sections below.
pT1 and pT2 Tumour size is part of TNM staging, with 40, 
70 and 100 mm being the boundary points for increasing 
stage categories (pT1a, pT1b and pT2a, respectively). The 
maximum diameter of the tumour (excluding any intravas-
cular extension), is assessed on macroscopic examination. 
For localised clear cell RCC, tumour size has been shown 
to correlate with clinical outcome, with increasing tumour 
size correlating with a worse prognosis [107]. Most tumours 
that exceed a maximum of 70 mm diameter show renal sinus 
involvement (fat or vascular invasion) and are, therefore, of 
higher stage [108].
pT3 The presence of perinephric fat invasion is part of TNM 
staging (pT3a). The nature of the invasive edge, whether 
pushing (rounded) or infiltrative, has been shown to have 
prognostic significance, with 3-year survival rates of 75% 
and 27%, respectively, although specification of the growth 
pattern is not currently a required item for pathology reports 
[109].
Renal sinus invasion, defined as invasion into sinus fat/
connective tissue or within vascular spaces, is the principal 
route of extra-renal spread of RCCs (pT3a). Through the 
extensive work of Bonsib, it is now recognised as a vital 
area for pathological assessment to ensure accurate staging 
[110–112]. The presence of renal sinus invasion has been 
shown to be associated with more aggressive tumour behav-
iour than perinephric fat invasion [113].
Only gross invasion of the renal vein or its ‘muscle con-
taining segmental branches’ is included in TNM7 stage 
pT3a. However, for TNM8, the requirement for ‘gross’ 
invasion is removed, as is the need for involved branches 
(tributaries) of the renal vein to contain muscle. The TNM8 
pT3a stage, therefore, includes the presence of any involve-
ment of the renal vein and its branches, whether identified 
grossly or microscopically.
Invasion of the pelvicalyceal system has been shown in 
some studies, including a meta-analysis involving over 9000 
patients, to be associated with poor survival and to reduce 
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recurrence-free survival [114–117]. It is not part of TNM7 
staging, but is included in TNM8 as pT3a.
pT3b is defined as involvement of the inferior vena cava 
(IVC) below the diaphragm and pT3c as IVC involvement 
above the diaphragm or if there is evidence of direct invasion 
of the vein wall at any level. In TNM8, the need for the IVC 
involvement to be visible grossly has been removed.
pT4 The presence of direct invasion of the ipsilateral adrenal 
gland has a poor outcome and is TNM stage pT4 [78, 84]. It 
is present in 2% of cases at nephrectomy and is more often 
seen in large tumours, those in the upper pole or those with 
vascular invasion [118]. Invasion of Gerota’s fascia, taken 
as the surgical margin of the fat at nephrectomy, is also pT4.
pN Palpable lymph nodes are found in the hilar region in 
less than 10% of nephrectomy cases [119]. Although sur-
vival rates fall progressively as the number of lymph nodes 
involved by metastatic tumour increases, the TNM staging 
has only two categories for regional node status: pN1 for 
one or more positive nodes and pN0 if they are uninvolved.
pM pM1 is the category assigned for pathologically proven 
distant metastases. Adrenal metastases are stage pM1, as 
are nodal metastases beyond the regional lymph nodes or at 
other distant sites.
Lymphovascular invasion
Lymphovascular (microvascular) invasion (other than that 
within the perinephric or renal sinus fat in stage pT3a) is 
not part of TNM staging. However, it has been reported to 
correlate with survival, independent of tumour size, grade 
or type, and to have prognostic significance in low-stage 
RCC, independent of tumour grade [120–123]. Lymphatic 
spread to hilar lymph nodes is less often seen in clear cell 
RCCs than in papillary RCCs or collecting duct carcinomas.
Surgical margins
All surgical margins are assessed routinely in pathol-
ogy, with margin involvement by tumour being generally 
regarded as a risk factor for local tumour recurrence. Patients 
with residual disease post-nephrectomy have poorer survival 
[124]. The presence of invasion of the renal vein wall at 
the surgical margin of the vein is also a risk factor for local 
recurrence [125]. Assessment of the parenchymal surgical 
margin is of importance for partial nephrectomy specimens, 
although one large study of over 3800 cases has shown a lack 
of correlation between the presence of a positive surgical 
margin and tumour recurrence [126].
Potential future improvements
Biomarkers
There is a need to develop more reliable and readily avail-
able biomarkers for immunohistochemistry that have diag-
nostic, predictive and prognostic utility. Similarly, devel-
opment of validated molecular tests and pathways for easy 
access to this advancing technology is necessary. Such 
tests need to be able to overcome the heterogeneity of renal 
tumours that affects grading and molecular characteristics in 
different regions of the tumour. Development of molecular 
tumour profiles may enable prediction of behaviour of those 
tumours for which the current WHO/ISUP grading system 
is not applicable or might obviate the need for microscopic 
assessment of tumour grade.
Any new tests need to be applicable to small biopsy sam-
ples. Biopsies of renal masses or metastases are becoming 
more frequent, being used to guide management of small 
renal masses and systemic treatments of metastatic disease. 
When an adequate sample has been achieved, renal biopsies 
have been shown to be highly sensitive and specific, with 
low complication rates [127, 128]. However, such samples, 
by virtue of the limited amount of tissue available and the 
heterogeneity of renal tumours, do pose problems with path-
ological diagnosis, tumour typing and assessment of grade 
[129, 130]. There is, therefore, a need to develop validated 
methods of utilising these small amounts of tumour tissue to 
obtain information critical for patient management.
Education and improved referral pathways
Many nephrectomy and biopsy specimens will be reported 
outside specialist centres. It is, therefore, crucial that 
pathologists in the wider community are able to recognise 
less familiar tumour types that potentially influence patient 
prognosis and management or have genetic implications. 
In the UK, for example, there is a national uropathology 
external quality assessment (EQA) scheme (www.histo patho 
logye qa.org) which has an educational role in improving 
standards. Pathologists are expected to participate in EQA 
schemes relevant to their areas of clinical practice, regularly 
assessing slides and receiving feedback on their performance 
in comparison with their peers. This type of activity and the 
availability of educational courses, guidelines and online 
resources have significantly improved knowledge of renal 
tumour pathology. Nonetheless, infrequent tumour types 
may be misdiagnosed. Referral for expert opinion is always 
an option, initiated by the reporting pathologist, but it is sug-
gested that for specific cases, such as tumours occurring in 
younger adults, or where there is a family history or presence 
of multiple tumours, there should be automatic referral to 
a specialist centre for pathology review. This is particularly 
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important where further FISH or molecular tests are deemed 
necessary.
Digital pathology
The advent of rapid whole-slide scanning technology, ena-
bling the production of high-resolution and high-quality 2D 
and 3D digital images from conventional glass slides, has 
brought with it considerable opportunities for the future 
practice of renal tumour pathology, as well as pathology 
as a whole.
In clinical practice, there are the potential advantages of 
remote reporting and for obtaining rapid second opinions, 
without the need for costly and time-consuming transpor-
tation of glass slides between laboratories. Work may be 
distributed digitally, from centres with staff shortages, to 
pathologists available at geographically distant centres, thus 
maintaining reporting turnaround times [131]. For rarer 
renal tumour entities, it is possible for pathologists to share 
images and to obtain rapid expert opinions from around the 
world. Case review for multidisciplinary team meetings is 
facilitated by enabling images to be shared across a number 
of centres simultaneously. Digital macroscopic and micro-
scopic images of specimens can also be incorporated into 
pathology reports and stored on hospital patient information 
systems.
Image analysis techniques have the potential to remove 
subjectivity and inter-observer variation from, for example, 
tumour grading, by enabling digital assessment of nucleolar 
size and nuclear features. The development of computer-
assisted diagnostics also enables automated assessment of 
morphological features, either to highlight areas of inter-
est to the pathologist, such as the highest grade areas of 
tumours, or to identify subtle features of prognostic signifi-
cance or predictive of response to therapy [132–134].
Immunohistochemistry for biomarker evaluation in 
research, either on series of tumour sections or on tissue 
microarrays, involves assessment of the intensity and distri-
bution of protein expression, often on a very large number 
of tumours. This is very laborious and time-consuming work 
and is subject to considerable inter- and intra-observer varia-
tion. Image analysis systems have the capability of not only 
speeding up analysis and handling high volumes, but may 
also remove the element of subjectivity inherent in manual 
assessment [135]. There is also potential for simultaneous 
assessment of multiple biomarkers on the same tissue sec-
tion. Pathologist input is, however, paramount for ensuring 
that the correct tissue area is assessed. Such technology is 
also potentially advantageous in clinical practice, as the 
introduction of any additional biomarker assessments adds 
work to an already stretched specialty [136].
For clinical trials, involving large numbers of centres, 
there is the opportunity to centrally review digital images 
of tumour samples, for quality assurance, and to maintain 
a central image library of cases for future analysis [137].
For teaching and education, digital pathology is also 
highly effective. ISUP now has an image database for uro-
logical pathology, which can be accessed online (www.isup.
org) and provides an invaluable resource of renal tumour 
images for reference and promotes standardisation of diag-
nosis and tumour grading [138, 139]. The capacity to anno-
tate digital images enhances the educational value.
The wider availability of digital pathology for diagnostic 
use will, however, require significant investment in equip-
ment, provision of efficient storage and retrieval facilities 
for the immense number of generated digital images, and for 
staff training. There is also a need to introduce guidelines 
and quality assurance checks to enable widespread use in 
clinical practice [140, 141]. Ultimately, it will require a cul-
ture change in the way pathology is practised in the future.
Conclusion
In recent years, there has been considerable progress in pro-
ducing guidance for pathologists in the assessment of renal 
tumours, thus improving consistency in diagnosis, grading 
and staging. The development of additional immunohisto-
chemical and molecular tests is needed to facilitate tumour 
typing, because of prognostic implications, and to enable 
more reliable identification of poorly differentiated meta-
static tumours as being of renal origin. Any new tests need 
to be applicable to small biopsy samples, to overcome the 
heterogeneity of renal tumours. There is also a need to facili-
tate identification of tumour types that have genetic implica-
tions. This may mean automatic referral of certain categories 
of patient or tumours to specialist centres or establishing 
national referral centres for expert review and further tests. 
Digital pathology has a potential role in facilitating such 
referral practice.
Tumour grading has established prognostic significance, 
but it is still based upon subjective microscopic assessment 
and the extent of tumour sampling. It is also not applicable 
to all renal tumour types. The WHO/ISUP system has advan-
tages over the former Fuhrman grading system, but finding 
ways of improving assignment of grade, enhancing its rel-
evance, or introducing an alternative means of categorising 
tumours is also important for future patient management.
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